Industry Partners Step Up To Help Blood Cancer Patients
WHITE PLAINS, N.Y., June 11 /PRNewswire/ -- Responding to an appeal for help, two companies, Celgene Corporation and Millennium: The Takeda Oncology Company, have stepped up to help blood cancer patients in their time of need with significant leadership gifts for The Leukemia & Lymphoma Society's Patient Financial Aid program.
The program provides funds to help patients access care. Today, more than ever, patients need financial assistance and LLS's program was facing a shortfall. The gifts from Celgene and Millennium will go a long way toward helping LLS continue to provide assistance to these patients for such expenses as travel and other costs related to medical treatment. The program helps remove barriers to patients wishing to participate in clinical trials by helping cover routine care costs. LLS projects that it will have more than 21,000 patients enrolled in the financial aid program this year.
"LLS is extremely grateful to Celgene and Millennium for their generosity," said LLS President and CEO John Walter. "Both companies have been steadfast supporters of LLS's patient services and education programs throughout the years, and both are continuing to demonstrate their commitment to addressing the financial burden faced by blood cancer patients, particularly during the current economic crisis."
To learn how your company can help, please contact Andi Ciminello at (914) 821-8869, or andi.ciminello@lls.org.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society (R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.
Contact: Andrea Greif
(914) 821-8958/andrea.greif@lls.org
SOURCE The Leukemia & Lymphoma Society
The program provides funds to help patients access care. Today, more than ever, patients need financial assistance and LLS's program was facing a shortfall. The gifts from Celgene and Millennium will go a long way toward helping LLS continue to provide assistance to these patients for such expenses as travel and other costs related to medical treatment. The program helps remove barriers to patients wishing to participate in clinical trials by helping cover routine care costs. LLS projects that it will have more than 21,000 patients enrolled in the financial aid program this year.
"LLS is extremely grateful to Celgene and Millennium for their generosity," said LLS President and CEO John Walter. "Both companies have been steadfast supporters of LLS's patient services and education programs throughout the years, and both are continuing to demonstrate their commitment to addressing the financial burden faced by blood cancer patients, particularly during the current economic crisis."
To learn how your company can help, please contact Andi Ciminello at (914) 821-8869, or andi.ciminello@lls.org.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society (R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.
Contact: Andrea Greif
(914) 821-8958/andrea.greif@lls.org
SOURCE The Leukemia & Lymphoma Society
posted by Paresh Paleja at
11:13 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home